Avalyn Pharma Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Avalyn Pharma Inc. (AVLN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Avalyn Pharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.79M, a 147.34% increase year-over-year.
- Avalyn Pharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.19M, a 119.71% increase year-over-year.
- Avalyn Pharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.13M.
- Avalyn Pharma Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $543.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $2.79M 10-Q · filed 2026-08-12 | $3.98M derived: sum of 2 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.19M 10-Q · filed 2026-08-12 | |
| 2025-06-30 | $1.13M 10-Q · filed 2026-08-12 | $1.67M derived: sum of 2 quarters · filed 2026-08-12 |
| 2025-03-31 | $543.00K 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |